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ABSTRACT 
The effects of i.c.v. administered dermorphin, a highly selective 
"-opioid agonist, on cardiac function and renal, mesenteric and 
hindquarter blood ftow were studied in conscious rats. Core 
temperature, blood gases, arterial plasma Ieveis of norepineph-
rine, epinephrine, dopamine, 3,4-dihydroxyphenylalanine and di-
hydroxyphenylacetic acid (DOPAC) also were examined. Cardiac 
output was rneasured using a thermodilution technique and 
regional blood ftows using directional pulsed Doppler velocime-
try. Dermorphin, at doses of 0.1-100 nmolfkg, increased blood 
pressure and hindquarter blood ftow, renal and mesenteric re-
sistance, and core temperature. Higher doses (1-5 ~/kg) 
caused respiratory depression, acidosis, and shock despite pro-
faund sympatho-adrenomedullary stimulation. Circulating Ieveis 
The heptapeptide dermorphin has a primary amino acid 
sequence that differs from any k.nown natural opioid peptide 
in that it contains o-alanine (Montecucchi et al., 1981; de 
Castiglione and Rossi, 1985). It nevertheless is a potent and 
long-acting opioid (Broccardo et al. 1981; Stevensand Yaksh, 
1986). In intact animals dermorphin produces analgesia and 
affects neuroendocrine, respiratory and cardiovascular vari-
ables (for review see Feuerstein, 1986). In in uitro studies 
dermorphin, like morphine, has a distinct pattern of actions 
consistent with a mu receptor agonist (Glaser et al., 1981; 
Westphal et al., 1985; Krumins 1987). The affinity of dermor-
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of catecholamines were significantly increased at the dermorphin 
doses of 0.1-1 00 nmolfkg. At the 100 nmolfkg dose, plasma 
Ieveis of epinephrine, norepinephrine, the dopamine metabellte 
dihydroxyphenylacetic acid and the catecholamine precursor 
3,4,-dihydroxyphenylalanine were increased by 2-15-fold. The 
data indicate that mu opioid receptor Stimulation exerts potent 
effects on cardiorespiratory functions, activates the sympathoad-
renomedullary system and produces a pattem of blood flow 
changes consistent with the stress-induced •detense· response 
(skeletal muscle vasodilation and splanchnic vasoconstriction). 
Excessive mu opioid receptor Stimulation Ieads to shock due to 
respiratory and hemodynamic collapse. 
phin binding to mu sites in the rat brain was almost three times 
greater than that of D-Ala2, MePhe\ Gly-ol"-enkephalin 
(DAGO; Krumins, 1987), which previously was considered to 
be the most potent and selective mu opioid agonist (Handa et 
al., 1981, Kosterlitz et al., 1980, Pfeiffer et al., 1982). 
Due to resistance of dermorphin to plasma and tissue pepti-
dases, it also is the most toxic natural opioid peptide known 
(de Castiglione and Rossi, 1985; Negri and Improta, 1984). We 
reported that minute amounts of dermorphin administered into 
brain parenchyma or the cerebroventricular. system caused 
severe respiratory depression and hypotension despite profound 
activation of the sympatho-ad.renomedullary system (Feuer-
stein and Faden, 1983b). The mechanism of dermorphin-in-
duced cardiovascular collapse is not fully understood, since 
none of the previous studies examined card.iac function or 
regional hemodynamics. The unique selectivity of dermÖrphin 
for the mu opioid receptors also provides an opportunity to 
assess the effects of the mu opioid receptor stimulation on 
autonomic functions. 
In the present study we report the effects of dermorphin on 
ABBREVIAnONS: MAP, mean arterial pressure; SAP, systolic arterial pressure; DAP, diastolle arterial pressure; Cl, cardiac index; TPAI, total 
peripheral resistance Index; VA, vascular resistance; NE, norepineptvine; EPI, epinephrine; DA, dopamine; OOPA, dihydroxyphenylalanine; OOPAC, 
dihydroxyphenylacetic acid; OAGO, o-Ala2 ,MePhe4 ,Giy-ol5 enkephalin. 
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discrete organ blood flow and cardiac function in conjunction 
with respiratory, thermoregulatory, and sympatho-adrenome-
dullary responses. All studies were conducted in conscious 
freely moving rats, since anesthesia can obscure tbe central 
actions of opiates on the cardiovascular system (Feuerstein, 
1985; Hassen and Feuerstein, 1987; Kayaalp and Kaymakcalan, 
1966). 
Materials and Methods 
Male Sprague-Dawley rats (300-360 g) were purchased from Taconic 
Farms (Germantawn, NY) and housed at 22"C with a 12:12 hr light/ 
dark cycle. After aurgical operations the rats were housed individually 
in plastic cages (21X27X16 cm) with food and water ad libitum. 
Measurement of cardiac output. Rats were anesthetized with 
ketamine (130 mgfkg i.m.) and acepromazine (1.3 mg/kg i.m.) and 
placed in a stereotaxic device (David Kopt Instruments, Tujunga, CA). 
A stainless steel guide cannula for i.c.v. injections was placed on the 
skull (coordinates from bregma: AP=-0.8 mm, L=1.2 mm) and r.xed 
with glue. PE-50 catheten were then inserted inta femoral vessels. The 
catheten were tunneled under the skin and exited at the nape of the 
neck. An incision was made at the midline of the neck from the cricoid 
ta the clavicle, and a PE-50 catheter was inserted inta the right atrium 
via the extemal jugular vein. The left common carotid artery was 
exposed and ligated, and a thermistar (MX2-780-33 model THMP f 
1.5, Teflon reusable, Columbus Instruments, Columbus, OH) was ad-
vanced througb the carotid inta the ascending aorta. Placement above 
the aortic valve was confirmed in each animal by the shape of the 
dilution curve and before tbe probe was finally sutured to the neck 
muscles and at the end of experiment. The jugular vein catheter and 
the thermistor were tunneled under the skin to tbe nape of the neck. 
All catheten and probe wire were secured by a soft spring wire attached 
ta the animal's neck using an adhesive collar. Twenty-four houn after 
the surgery the arterial line was connected to a pressure transducer 
(Narco Bio-Systems model RP 1500i) coupled to a strain gauge coupler 
(Narco Bio-Systems type 7032). Blood pressure (mean, systalic, dia-
stolic, pulse) and heart rate were continuously recorded on a Narcotrace 
80 computerized pbysiograph and sampled automatically every 30-60 
sec by a Northstar-Hazeltine computer. 
Cardiac output was measured by thermodilution technique as de-
scribed (Siren et al., 1988). In brief, tbe thermistorwas attacbed to tbe 
computerized Cardiomu II (CMX2-780-k with microprobe option R, 
Columbus Instruments, Columbus, OH). The dead space of tbe venous 
line was first flushed with 50 ~1 of 0.9% (wt/vol) NaCl (saline) at room 
temperature (22"C); after a brief stabilization period an additional 
injection of 200 ~1 normal saline (22"C) was rapidly injected using a 1-
ml syringe. A control period of 15 min included two or three cardiac 
output recordings ta test for consistency and placement of the probe. 
During this period control values for blood pressure and heart rate also 
were collected. The timer for automatic data collection was started and 
data points collected immediately before and 2, 5, 15, 30 and 45 min 
after dennorphin injection. Total peripheral resistance was calculated 
by dividing tbe mean arterial pressure by the cardiac output; values of 
cardiac output and TPR were further indexed per unit of weigbt. Core 
temperature was monitared by the aortic thermoprobe before eacb 
cardiac output measurement. 
Increasing doses of dermorphin were injected i.c.v. in 5 ~1 saline 
slowly over 30 sec by means of a premeasured 30 gauge cannula (7.5 
mm), and the cardiovascular index were monitared for 45 min for each 
dose. The proper position of the i.c.v. cannula was ascertained at the 
end of the experiment by an injection of dye (methylene blue, 5 ~1) into 
the ventricular space. 
Measurement of organ blood ftow. The directional pulsed Dop-
pler velocimetry method was selected to measure organ blood flow in 
hindquarter, renal and mesenteric arteries. Though it does not allow 
quantitative blood flow monitaring, this metbad is superior compared 
with other available techniques, since 1) it can be used chronically in 
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conscious animals, 2) it allows continuous on-line recording of blood 
flow and 3) it can detect instantaneous transient changes in blood flow 
within seconds after drug administration. Haywood and co-workers 
(1981) demonstrated that the velocity signals recorded from the Dop-
pler flow probes are directly and reliably proportional to changes in 
true volume flow measured by electromagnetic flowmetry. 
Each rat to undergo regional hemodynamic measurements was an-
esthetized with ketamine-acepromazine, and a guide cannula for i.c.v. 
injections was placed on the skull as described above. A midline 
laparotomy was tben made, and the left renal and superior mesenteric 
arteries and lower abdominal aorta above its bifurcation were carefully 
isolated under a dissecting microscope. Doppler flow probes (V alpey-
Fisher, Hopkinton, MA) were then loosely sutured araund each vessel 
as described earlier (Haywood et al., 1981; Sirim et al., 1988). The 
insulated wire Ieads were fixed ta the back muscles, tunneled under the 
back skin to exit at the neck, and soldered to a receptacle that was 
then attached to the skull using small screws and dental acrylic. The 
animals were allowed to recover from the surgery for 7 days. Twenty-
four houn before the experiment the rat was reanesthetized with 
halothane (2% in oxygen), and femoral artery and vein were catheter-
ized with PE-50 tubing. The catheters were tunneled under the back 
skin, exited at the nape of the neck and secured by a soft spring wire 
as described above. 
On the day of the experiment, the arterial catheter was connected 
to a pressure transducer (Narco), and blood pressure and heart rate 
were continuously recorded on the Narcotrace 80 physiograph. A cable 
connecting the blood flow receptacle and the Doppler flowmeter (Uni-
venity of Iowa, Bioengineering Facility, model 545C-4) was attached 
to the animal, and the mean blood flow was continuously recorded on 
the physiograph. V ascular resistance was calculated by dividing the 
mean arterial pressure by blood velocity (Doppler shift in kilohertz) as 
described (Haywood et al., 1981; Sirin et al., 1988). Changes in blood 
flow and vascular resistance are expressed as a percent of control 
values. 
Increasing doses of dermorphin were injected i.c. v. in 5 ~o&l saline over 
30 sec and all indexes followed continuously for 30-45 min for each 
dose. 
Auay of blood pC02 , p02 pH. Blood samples (0.2 ml) were 
withdrawn from the arterial catheter 30 min after injection of dermor-
phin (1, 100 or 1000 nmol/kg). An equal volume of fresh rat blood was 
used ta replace the amount withdrawn. Blood pC02, p02 and pH were 
assayed using a Coming pH-blood gas analyzer (model165/2, Coming 
Instruments, Coming, NY). 
Auay of plasma catecholaminee. Blood samples (0.8 ml) were 
withdrawn from the arterial catheter 30 min after dermorphin admin-
istration (0.1, 1 and 100 nmol/kg). The blood withdrawn was replaced 
with an equal volume of fresh rat blood. Blood specimens were collected 
in chilled test tubes, centrifuged (Beckman microfuge B) for 1 min, 
and the plasma removed and rapidly frozen on dry ice. Epinephrine 
(EPI), norepinephrine (NE), dopamine (DA), catecholamine precursor 
3,4-dihydroxypbenylalanine (DOPA), and the dopamine metabolite 
dihydroxypbenylacetic acid (DOPAC) were separated by alumina ex-
traction and assayed by high performance liquid chromatagraphy with 
electrochemical detection (Goldstein et al., 1985; Eisenhafer et al., 
1986). 
Dermorphin (Tyr-o-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) was purchased 
from Sigma (St. Louis, MO), and naloxone was kindly provided by 
DuPont Pharmaceuticals (Wilmington, OE). Both drugs were dissolved 
in 0.9% NaCl (saline). 
Statiatical analysis. Data are presented as means ± S.E. for the 
given number of rats. One-way analysis of variance followed by Dun-
nett'& test, Student-Newman Keul's test or the Kruskal-Wallis test 
(Theodorsson-Norheim, 1986) was used for statistical analysis as ap-
propriate. A significant difference was defined by P < .05. 
Results 
Effect of dermorphin on blood pressure and heart rate. 
The baseline values for hemodynamic variables before dermor-
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phin administration were not statistically different from the 
control values before saline injection (table 1). Dermorphin 
i.c.v. produced a bell-shaped response of mean arterial pressure 
(MAP) as a function of dose (fig. 1). The doses of 0.1-100 
nmol/kg increased MAP, whereas higher doses ( 1-5 ~mol1kg) 
produced smaller pressor responses or even decreased MAP 
(fig. 1). Dermorphin at doses of 10 nmol/kg to 1 ~mol/kg 
significantly increased systolic arterial pressure (SAP) and 
slightly increased diastolic arterial pressure (DAP). At 5 ~mol/ 
kg, dermorphin decreased DAP (tig. 2). Pulsepressure therefore 
increased after i.c.v. dermorphin with maximal pressor re-
sponses reached at 10 and 100 nmol/kg (tig. 1). The maximum 
increases in MAP and pulse pressure were achieved 5 min after 
the dermorphin administration and subsided in 30-45 min. 
Heart rate first decreased and then slowly increased after 
dermorphin (1-100 nmol/kg). The muimum bradycardic re-
sponse was reached 5-15 min after drug injection; tachycardia 
was maximal 30-45 min after injection. The peak bradycardic 
effects are shown in figure 1. The muimum tachycardic re-
sponse after the 1 nmol/kg dose was 54±10 bpm (P<.01 versus 
saline). The corresponding responses after the 10 and 100 nmol/ 
kg doses were 64±13 bpm (P<.01 versus saline) and 105±15 
bpm (P<.01 versus saline). High doses of dermorphin (1-5 
~mol/kg) induced only tachycardia (fig. 1). 
Effect of dermorpbin on cardiac output and TPRI. 
Dermorphin i.c.v. increased cardiac index (Cl) at the doses of 
1 nmol/kg to 1 ~mol/kg (fig. 3). The muimum increase in CI 
(106±14 ml/min/kg, P<.Ol) was achieved 15 min after the 1 
"mol/kg dose. The CI was still significantly elevated 30 min 
after the 10 nmol/kg to 1 ~mol/kg doses of dermorphin. Total 
peripheral resistance index (TPRI) tended to increase shortly 
after the 10 nmol/kg dose; at high doses (1-5 ~mol/kg) der-
morphin decreased TPRI (fig. 3). 
Effect of dermorpbin on organ blood flow. At the 0.1 
nmol/kg to 1 ~mol/kg doses, dermorphin i.c. v. induced a sig-
nificant increase in hindquarter blood flow; at higher doses a 
later decrease in hindquarter blood flow was found, and the 
highest dose induced only a fall in hindquarter blood flow (fig. 
4). The blood flow in mesenteric artery significantly decreased 
after the 10 nmol/kg and 1 ~mol/kg doses of dermorphin, and 
the other doses bad no significant effect on mesenteric blood 
flow (fig. 4). Blood flow in the renal artery decreased in a dose-
TABLE 1 
S.ee-llne levela of hemodynamlc varillblea before aallne or 
dermorphln admlnletratlon 
PP. pulse pressure; BF, blood flow; HR, heart rate. Values are means :t S.E. n, 
runbar of rats in each group. 
Vnble Saline Dermorphin 
MAP(mmHg) 17 114 ± 2 112 ± 2 
SAP(mmHg) 17 149 ±3 152 ±3 
OAP(mmHg) 17 92 ± 3 88±5 
PP(mmHg) 17 57 ±3 58±3 
HA (bpm) 17 403 ± 10 397 ± 13 
Cl (ml/mlnJkg) 17 421 ± 10 425 ± 12 
TPRI (mmHgJml/mlnJkg) 17 0.27 ± 0.01 0.27 ± 0.01 
Blood ftow (kHz) 
Hlndquarter 14 4.6 ± 1 5.0± 1 
Renal 14 5.0 ± 1 5.5 ± 1 
Mesenteric 14 4.0 ± 1 4.0± 1 
Vascular reslstance 
(mmHgJkHz) 
Hlndquarter 14 39±8 35±6 
Renal 14 35 ±7 24±4 
Mesenteric 14 36±5 39±4 
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Flg. 1. Effect of i.c.v. dermorphin on MAP, pulse pressure (PP) and heart 
rate (HA) in the conscious rat. Values are means ± S.E. and represent 
maximum changes after saline (open circles) or dermorphin (dosed 
circ~es). Number of rats in each group is in parenthesis. Asterisks, 
statistical significance versus saline by Dunnett' s test. 
related manner at the 10 nmol/kg to 5 ~mol/kg doses of 
dermorphin (fig. 4). 
Effect of dermorphin on regional vascular resistance. 
The hindquarter vascular resistance decreased after the 0.1 
nmol/kg dose of dermorphin (-24±5%, P<.05); the 10 and 100 
nmol/kg doses also decreased hindquarter vascular resistance 
initially but thereafter produced a Ionger-lasting hindquarter 
vasoconstriction (47±18%, P<.01) (fig. 5). The 5 ~mol/kg dose 
of dermorphin increased hindquarter vascular resistance (fig. 
5). 
The renal vascular resistance increased dose-dependently 
after dermorphin administration (tig. 5). The muimum vaso-
constrictor response (138±36%, P<.01) was reached 10 min 
after the 100 nmol/kg dose, and the vascular resistance was 
still signiticantly elevated 30 min after this dose. 
Between doses of 10 and 100 nmol/kg dermorphin induced 
mesenteric vasoconstriction (tig. 5). The 10 nmol/kg dose grad-
ually increased mesenteric vascular resistance up to a muimum 
of 113±24% (P<.01) 30 min after the injection. At the 100 
nmol/kg dose the muimum increase in mesenteric vascular 
resistance (100±20%, P<.01) became apparent 2 min after 
dermorphin and subsided in 20 min. 
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Flg. 2. Effect of i.c.v. dermorphin on SAP and OAP in the conscious rat. 
Values are means ± S.E. and represent maximum changes after saline 
(open circles) 01' dermorphin (cioSed circles). Number of rats in each 
group is in parentheses. Asterisks, statistical significance versus saline 
by Dunnett's test. 
Effect of dermorphin on plasma concentration of NE, 
EPI, DA, DOPA and DOPAC. As shown in figure 6 groups 
to be treated with saline or dermorphin bad similar baseline 
Ievels of EPI, and of NE, with base-line catecholamine values 
in agreement with those of previous studies (Pfeiffer et al., 
1983a,b; Feuerstein and Faden, 1983a,b). Dermorphin at doses 
of 0.1-100 nmol/kg increased plasma EPI and NE in a dose-
related manner (fig. 6). At 0.1 nmol/kg plasma EPI increased 
by almost 4-fold and plasma NE by approximately 50%. The 1 
nmol/kg dose increased plasma EPI by 7 -fold and NE by 1.5-
fold. The 100 nmol/kg dose increased plasma EPI by 15-fold 
and NE by 8-fold. At this dose DA was elevated 2-fold (from 
129±15 to 334±39 pg/ml, n=5, P<.01); the DA metabolite 
DOPAC was increased by over 3-fold (from 315±41 to 998± 
121 pg/ml, n=5, P<.Ol) a:od DOPA by 2-fold (from 899±58 to 
1669±167 pg/ml, n=5, P<.05). 
The changes in plasma NE induced by dermorphin were in 
correlation with its pressor (r=0.972, P=.05) and renal constric-
tor (r=0.995, P=.01) effects. There was also a significant cor-
relation between the increase in plasma EPI and the tachy-
cardic response to dermorphin (r=0.957, P=.05). 
Effect of dermorpbin on core temperature. Core tem-
perature increased at dermorphin doses of 0.1 nmol/kg to 1 
"molfkg. The increment in core temperature was dose-depend-
ent to a maximum change of approximately 2•c (fig. 7). After 
the highest dose (5 "molfkg) the temperature tended to decline 
back to base line Ievel (fig. 7). 
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Flg. 3. Effect of i.c.v. dermorphin on Cl and TPRI in the consciouS rat. 
Values are means ± S.E. and represent maximum changes after saline 
(open circles) 01' demorphin (closed circles). Number of rats in each group 
is in parentheses. Asterisks, statistical significance versus saline by 
Dunnett's test. 
Effect of dermorpbin on blood gases. The blood pH, pO:l 
and pC02 were all in a normal range after the 1 nmol/kg dose 
of dermorphin but with a slight but significant decrease in pO:l 
(table 2). The higher doses, 100 nmol/kg and 1 #'mol/kg, pro-
duced severe respiratory acidosis of similar magnitude (table 
2). 
Effect of naloxone on hemodynamic responses pro-
duced by · dermorphin. In a separate set of rats, the effects 
of a single dose of dermorphin (10 nmol/kg) on the cardiovas-
cular system were monitared after treatment with saline or 
naloxone (fig. 8). In this experiment dermorphin was injected 
i.c.v. in rats treated with naloxone (5 mg/kg i.v.) 20 min before 
dermorphin administration. Naloxone totally blocked the pres-
sor response, reversed the bradycardia and attenuated the 
increase in cardiac output produced by the 10 nmol/kg dose of 
dermorphin. 
The potency of naloxone (5-20 mg/kg i.v.) to reverse the 
changes in blood pressure, heart rate and organ blood flow 
produced by high doses of dermorphin (1-5 ~o~mol/kg) was 
studied in 11 additional rats. Three of 11 rats were still alive 
24 hr after dermorphin administration; the remaining eight 
animals died within 10 min after the dermorphin injection 
despite the i.v. injection of naloxone (10-20 mgfkg) 2-10 min 
after dermorphin. The animals that ultimately died despite 
naloxone treatment experienced further decreases in renal and 
mesenteric blood flow and increases in vascular resistance after 
naloxone administration (table 3). In the surviving animals 
naloxone (5-10 mg/kg i.v.) significantly increased blood flow 
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Flg. 4. Effect of i.c. v. dermorphin on organ blood flow in hindquarter, 
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Flg. 5. Effect of i.c.v. dermorphin on vascular resistance in hindquarter, 
renal and mesenteric vessels of the conscious rat. Values are means ± 
S.E. and represent maxlmum changes after sallne (open symbols) or 
dermorphin (closed symbols); n, number of rats. Asterisks, statistical 
significance versus saline by Dunnett's test. 
and decreased vascular resistance in the renal and mesenteric 
circulation but did not affect blood pressure, heart rate or 
hindquarter blood flow and resistance (table 3). Figure 9 shows 
an authentic chart recording demonstrating the influence of 
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Flg. 7. Effect of i.c.v. dermorphin on body temperature (T) in the con-
scious rat. Control values (hatched circle) and maximal values after sallne 
(open circle) or dermorphin (closed circ:les) are given as means ± S.E. 
Number of rats in each group is in parentheses. Asterisks, statistlcal 
significance versus saline and control by Student-Newman-Keul's test. 
TABLE2 
Effect of l.c.v. dermorphln on blood gaMa ln the conacloua rat 
Values are mean ± S.E. at control and 30 min after dermorphin are given: n, 
number of rats. 
Group BloodpH pCOz p()z 
mmHg 
Control 18 7.36 ± .01 35 ± 1 97 ± 1 
Dermorphin 
1 nmol/kg 7 7.31 ± .01 33 ± 1 89 ± 3"" 
100 nmol/kg 7 7.13 ± .03 .. sa ± s·· 42 ± 4"" 
1~o~mol/kg 4 7.19 ± .04"" 10 ± s·· 38 ± 3"" 
•• P < .01 by Student-Newman-Keul's test. 
naloxone on dermorphin-induced cardiovascular derangements 
in both these situations. 
Discussion 
The present results confirm and extend previous reports that 
dermorphin is an extremely potent agent affecting key hemo-
dynamic and autonomic functions. Cardiovascular effects of 
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L 
c 
~ 
0 Dennorphin, 
10 nmol/kg (8) 
<1 
• Naloxone 
+ 
Dennorphln, 10 nmol/kg 
(3·5) 
• p <0.05 
•• p <0.01 • vso 
6 
! 
3.2f 
3.1 • 
3.0 6 
TABLE3 
a: 
:c 
<1 
0"---'---
~-o.J-~ 
- 0.10[ 
Flg. 8. lnftuence of naloxone on the hemodynamic effects of 
dermorphin in the conscious rat. Naloxone (5 mg/kg) was 
injected into the jugular vein 20 min before i.c. v administra-
tion of a single dose of dermorphin (1 0 nmol/kg). Control 
values and peak changes after dermorphin administration 
are presented as mean ± S.E.; n, number of rats. Asterisks, 
statistlcal signiflcance between naloxone and saline treated 
group by Student-Newman-Keul's test. HR, heart rate. 
Effect of naloxone on hemodynamic variable• after dennorphln admlnlatntion 
Naloxone (5-10 mgJkg) was injected i.v. 2-10 min after dermorphin (1-5 x 10 ... mol/kg i.c.v.). Values are means ± S.E. Changasare calculated from control fOf' 
dermorphin ancl from the Ievei immediately before naloxone injection fOf' naloxone. Changas in blood ftow and resistance are given as percent values. 
Control DermorJnn 
Rats died (n = 8) 
MAP(mmHg) 138 ±8 -10 ± 15 
HR (bpm) 380 ± 24 -125 ± 31** 
Blood ftow• (kHz) 
Hindquarter 5.7 ± 0.9 -84 ± 9 .. 
Renal 7.0 ± 0.9 -55± 13** 
Mesenteric 4.8 ± 0.4 -82 ± 7** 
Resistance (mmHg/kHz) 
Hindquarter 32 ±7 670 ± 179** 
Renal 27 ± 8 276 ± 148** 
Mesenteric 39 ±9 509 ± 181** 
Rats recuperated (n = 3) 
MAP(mmHg) 136 ±8 -31 ± 12 
HR (bpm) 391 ± 36 34 ± 60 
Blood ftow • (kHz) 
Hindquarter 6.7 ± 0.5 -14 ± 22 
Renal 5.2 ± 0.7 -65 ± 16** 
Mesenteric 6.6 ± 0.9 -62±9 
Resistance (mmHg/kHz) 
Hindquarter 20±3 4±24 
Renal 27 ± 5 100 ± 33*• 
Mesenteric 22±4 126 ± 43** 
• Rats in first group died within 10 min. 
"P< .05 . 
•• p < .01. 
dermorphin were biphasic, similar to the responses reported by 
Pfeiffer et al. (1983a,b) using the selective m.u opioid agonist 
DAGO (Handa et al., 1981). In the present study increases in 
SAP, pulse pressure and CI were produced by low doses of 
dermorphin, and high doses produced a depressor response due 
1 "*' 
-8 ± 15 
-25 ± 40 
-95 ± 109 
24±46 
140 ± 165 
63±66 
51 ±84 
8±62 
19 ± 12 
8±41 
42 ±34 
159 ± 22** 
174 ± 110* 
-13±9 
-48 ± 7* 
-34 ±44 
3 "*' 
-34± 26 
17± 49 
-17.85 
-66± 22* 
-91 ±8 
-8±33 
1844 ± 719* 
104±51* 
33± 16 
41 ±35 
38±43 
156 ± 76** 
225± 194* 
4± 18 
-40± 13 
-36± 34 
30 m• 
13 ± 10 
-32 ± 16 
28± 38 
216 ± 183** 
211 ± 179* 
-12 ± 24 
-47 ± 21 
-49 ± 19 
to a decline in TPRI. In a previous study from this laboratory 
dermorphin i.c.v. at similar doses (0.3-150 nmol/kg) produced 
increments of SAP and DAP similar to those found in the 
present study (Feuerstein and Faden, 1983a,b), with a dose-
related bradycardia. In the present study bradycardia was pro-
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duced by low doses of dermorphin, whereas at higher doses its 
hemodynamic responses included a marked tachycarrlia. Other 
investigators reported increases in heart rate and, to a lesser 
degree, blood pressure after local administration of dermorphin 
(40 pmol) into the preoptic-anterior hypothalamic region of 
halothane-anesthetized rats (Diz et al., 1984, Diz and Jacobo-
witz, 1984). 8oth bradycardic and tachycardic responses to 
centrally injected dermorphin can be explained by stimulation 
of mu opioid receptors, since stimulation of the central mu 
opioid receptors with agonists such as DAGO, morphiceptin 
and morphine typically induces a biphasic heart rate response, 
bradycardia followed by tachycarrlia in the rat (see Feuerstein 
and Siren, 1987a,b). 
Regional hemodynamic responses to low doses of dermorphin 
included increases in renal and mesenteric vascular resistance 
and consequently progressive decreases in blood flow. An op-
posite response, vasodilation, was clearly seen in the hind-
quarter skeletal muscle. This pattern of regional hemodynamic 
changes was reported in sturlies using i.c.v. or intraparenchymal 
injections of the selective mu agonist DAGO in the conscious 
rat (Feuerstein and Siren, 1987b; Siren and Feurerstein, 1987). 
After the higher doses of dermorphin, the vasoconstriction 
rliminished, possibly due to the development of acidosis, which 
is known to cause vasodilation and decrease the sensitivity of 
-
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Fig. 9. Original chart recordings 
demonstrating the effect of nalox-
one on the hemodynamic re-
sponses to a high l.c.v. dose of 
dermorphin (1 "mol/kg) in the con-
scious rat. Panel A, rat that did not 
survive; panel B, example of the 
benefidal effect of naloxone (N) 
after dermorphin (0). AP, arterial 
pressure; HO, hlndquarter; R, 
renal, M, rnesenterlc. N • nalox-
one, To, T,o denote time points 
before/after dermorphin treat-
ment. 
vascular smooth muscle cells to catecholamines (Astrup 1968; 
Ford et al., 1968). 
The increases in blood pressure, mesenteric and renal vas-
cular resistance and hindquarter skeletal muscle vasodilation 
are consistent with activation of the sympatho-adrenomedul-
lary system. This suggestion is supported by the increased 
circulating Ievels of all catecholamines. Similar results have 
been reported showing }arge increments in circulating Ievels of 
EPI and NE after i.c.v. administration of dermorphin (Feuer-
stein and Faden 1983; Diz and Jacobowitz 1984) and other mu 
opioid agonists (Pfeiffer et al., 1983a,b; Kiritsy-Roy et al., 1986; 
Appel et al., 1986). Other sturlies from our laboratory have 
revealed rlirect activation of renal sympathetic nerve activity 
by centrally administered DAGO in the rat (Siren and Feuer-
stein, 1987). In the present study a significant increase in 
plasma EPI and NE was observed even after the lowest dose of 
dermorphin (0.1 nmol/kg) with increases in EPI predominat-
ing. This dose bad no effect on systemic hemodynamic variables 
but induced a vasodilation in hindquarter vasculature, a pattem 
that could be attributed to circulating EPI. Since plasma cate-
cholamines were markedly elevated at doses of dermorphin that 
did not produce consistent respiratory changes, sympatho-
adrenomedullary activation probably was not secondary to 
1989 
respiratory acidosis and seemed to be a primary mechanism 
determining the hemodynamic responses of dermorphin. 
The mu opioid agonists when administered centrally are 
known to increase plasma Ievels of NE and EPI (Pfeiffer et al., 
1983a,b; Feuerstein and Faden, 1982a,b; Kiritsy-Roy et al., 
1986). In the present study, Ievels of DA, DOPA and DOPAC 
also increased significantly after dermorphin administration at 
high doses. The elevated Ievels of DOPAC, a key metabolite of 
DA, and DA could have resulted from release of both from 
noradrenergic nerves or the adrenal medulla. Consistent with 
enhanced synthesis and release of catecholamines, Ievels of 
DOPA, the precursor of the catecholamines and the immediate 
product of the rate-limiting step in catecholamine biosynthesis, 
appro:a:imately doubled. Increased activity of tyrosine hydro:a:-
ylase, the rate-limiting step in DOPA production, is known to 
occur during intense sympatho-adrenomedullary Stimulation 
(Kopin, 1985), and circulating DOPA appears to be derived 
substantially from sympathetic nerve endings ( Goldstein et al., 
1987). 
The pronounced increase in the sympatho-adrenomedullary 
activity could have been the cause for the increase in cardiac 
outputthat was maintained even after the high doses of der-
morphin. Additional factors that might contribute to the in-
crease in CI are a) increase in heart rate, b) increase in preload 
due to catecholamine mediated venoconstriction and c) increase 
in cardiac contractility mediated by the increase in sympathetic 
activity and circulating EPI. At the high doses of dermorphin, 
respiratory acidosis could have counteracted the effects of 
sympathetic stimulation leading eventually to circulatory col-
lapse. 
The high Ievels of plasma NE and especially of EPI probably 
also contributed to the effects of dermorphin on the hind-
quarter, mesenteric and renal circulation. Whereas NE is a 
constrictor in most vascular beds, EPI causes vasodilation in 
skeletal muscle (Berecek and Brody, 1982; Siren et al., 1988). 
Thus, the differential effects of EPI and NE on hindquarter 
vasculature, but the synergistic effect on the renal and mesen-
teric vessels can explain the pronounced constriction of the 
renal and mesenteric vasculature and the dilator response of 
the hindquarter blood vessels at low doses of dermorphin. 
Similar hemodynamic and sympathetic responses to those pro-
duced by the mu opioid agonist dermorphin can also be elicited 
by electrical or chemical Stimulation of the hypothalamic and 
periaqueductal brain nuclei (Berecek and Brody, 1982; Yardley 
and Hilton, 1986; Stoddard et al., 1987; Siren and Feuerstein, 
1987). These brain areas are important for the integration of 
the stress-induced autonomic and behavioral defense responses 
(Yardley and Hilton, 1986). Since mu opioid receptors are 
abundantly present in these areas (Quirion et al., 1983), the 
present results Iead to the hypothesis that mu opioid stimula-
tion in these brain areas may be related to the neuroendocrine 
and hemodynamic changes associated with stress responses. 
In animals e:a:posed to high (micromole) doses of dermorpbin, 
cardiovascular collapse developed within a few minutes. This 
shock state was characterized by almost complete cessation of 
blood flow to the peripheral organs despite normal systemic 
arterial pressure. Attempts to reverse the shock by large doses 
of nalo:a:one failed in most animals. Only in the few animals 
where the hemodynamic changes produced by dermorphin were 
moderate did naloxone improve the cardiovascular status as 
indicated by substantial improvement of the circulation in the 
splanchnic area. 
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The use of the aortic thermistor also disclosed the effect of 
mu opioid receptor stimulation in increasing body temperature, 
which was not observed in our previous study (Feuerstein and 
Faden, 1983b) in which a rectal temperature probe was used. 
Since the body temperature was increased even after the lowest 
dose that bad no behavioral effects, the hyperthermic effect of 
dermorphin was not a result of the increased muscle tone and 
catalepsy characteristic of high doses of dermorphin (lmprota 
and Guglietta, 1985; Paakkari and Feuerstein, 1988). The mu 
opioid receptors have been suggested to mediate the hyper-
thermic action of morphine and other opioids, since these 
effects are naloxone reversible (Clark and Clark, 1980). How-
ever, the thermoregulatory responses to opiates show !arge 
variation depending on animal species, ambient temperature 
and the presence of restraint (for review, see Clark 1981). 
In summary, the results indicate that stimulation of mu 
opioid receptors produces a redistribution of organ blood flow 
most likely resulting from activation of the sympatho-adreno-
medullary system. Cardiovascular collapse and shock produced 
by high doses of dermorphin probably are due to severe vaso-
constriction leading to organ ischemia that is confounded by 
respiratory depression and especially hypoxemia. An interest-
ing new observation made in this study is the unique pattern 
of hemodynamic responses to mu opioid stimulation similar to 
the stress-induced defense response; these similarities may be 
due to the same fmal common pathway of sympatho-adreno-
medullary activation. Further studies are needed to evaluate 
whether endogenaus mu opioid peptides can mediate the car-
diovascular responses to stress. 
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